Trial Outcomes & Findings for Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine (NCT NCT02747186)

NCT ID: NCT02747186

Last Updated: 2018-12-19

Results Overview

Subjects' maxillary molar teeth will be tested before anesthetic and every 30 minutes with cold and electronic pulp test for presence of anesthesia as reported by subjects yes or no.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

24 participants

Primary outcome timeframe

Every 30 minutes up to 120 minutes Total

Results posted on

2018-12-19

Participant Flow

Participant milestones

Participant milestones
Measure
Buffered 1% Lidocaine, Then Non-Buffered 2% Lidocaine
At each treatment visit, participants were injected orally for maxillary field block (Posterior alveolar, Anterior alveolar, Palatal nerves).
Non-Buffered 2% Lidocaine, Then Buffered 1% Lidocaine
At each treatment visit, participants were injected orally for maxillary field block (Posterior alveolar, Anterior alveolar, Palatal nerves).
First Intervention
STARTED
12
12
First Intervention
COMPLETED
12
12
First Intervention
NOT COMPLETED
0
0
Washout (1 Week)
STARTED
12
12
Washout (1 Week)
COMPLETED
12
12
Washout (1 Week)
NOT COMPLETED
0
0
Second Intervention
STARTED
12
12
Second Intervention
COMPLETED
12
12
Second Intervention
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=24 Participants
Participants who were randomized to receive either Buffered 1% Lidocaine or Non-Buffered 2% Lidocaine
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
24 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
24 Years
n=5 Participants
Sex: Female, Male
Female
14 Participants
n=5 Participants
Sex: Female, Male
Male
10 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
24 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Every 30 minutes up to 120 minutes Total

Subjects' maxillary molar teeth will be tested before anesthetic and every 30 minutes with cold and electronic pulp test for presence of anesthesia as reported by subjects yes or no.

Outcome measures

Outcome measures
Measure
Buffered 1% Lidocaine
n=24 Participants
All subjects who received Buffered 1% Lidocaine.
Non-Buffered 2% Lidocaine
n=24 Participants
All subjects who received Non-Buffered 2% Lidocaine.
Mean Time to Pulpal Response After Maxillary Molar Anesthesia
98.8 minutes
Standard Deviation 30.6
84.5 minutes
Standard Deviation 27

PRIMARY outcome

Timeframe: Every 30 minute up to 120 minutes total

Subjects' maxillary molar teeth will be tested before anesthetic and every 30 minutes with cold and electronic pulp test for presence of anesthesia as reported by subjects yes or no.

Outcome measures

Outcome measures
Measure
Buffered 1% Lidocaine
n=24 Participants
All subjects who received Buffered 1% Lidocaine.
Non-Buffered 2% Lidocaine
n=24 Participants
All subjects who received Non-Buffered 2% Lidocaine.
Mean Time to Pulpal Response After Maxillary Canine Anesthesia
77.1 minutes
Standard Deviation 30.8
70.9 minutes
Standard Deviation 35.3

Adverse Events

Buffered 1% Lidocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Non-Buffered 2% Lidocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Raymond P. White Jr., DDS, PhD

University of North Carolina at Chapel Hill

Phone: 919-537-3944

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place